3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
25
Neoplasm Metastasis
6
Ovarian Neoplasms
5
Endometrial Neoplasms
5
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Site
2
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Melanoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Genital Neoplasms, Female
1
Genetic Diseases, Inborn
1
Fallopian Tube Neoplasms
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
ribociclib
1
palbociclib
1
capivasertib
1
abemaciclib
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced (Inoperable) or Metastatic Breast Cancer
×
Fulvestrant
×
30 days
×
Clear all
NCT04862663
2026-05-27
CAPItello-292
AstraZeneca
Phase 3
Recruiting
895 enrolled